Cetuximab (CTX) is an epidermal growth factor receptor (EGFR) inhibitor [65,193], and etoposide (ETP) is a topoisomerase-II blocker, which are loaded with DNA biodots in liposomes for targeted imaging and treatment of advanced-stage NSCLC (Figure 4a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.